STOCK TITAN

Ascendis Pharma - ASND STOCK NEWS

Welcome to our dedicated page for Ascendis Pharma news (Ticker: ASND), a resource for investors and traders seeking the latest updates and insights on Ascendis Pharma stock.

Ascendis Pharma A/S (ASND) delivers innovative biopharmaceutical solutions through its proprietary TransCon platform, focusing on rare endocrine disorders, oncology, and growth-related conditions. This news hub provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and strategic initiatives.

Access timely reports on ASND's product pipeline including TransCon PTH for hypoparathyroidism and TransCon CNP for achondroplasia. Our curated news collection covers earnings announcements, partnership developments, and European Medicines Agency (EMA)/FDA regulatory interactions, offering critical context for understanding the company's growth trajectory.

Key updates include progress in global clinical trials, manufacturing expansions, and analyses of commercial strategies for approved therapies. Bookmark this page for consolidated access to verified press releases and objective third-party analyses of ASND's position in the competitive biopharma landscape.

Rhea-AI Summary

Ascendis Pharma has announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date for TransCon PTH (palopegteriparatide), a treatment for adults with hypoparathyroidism, by three months to August 14, 2024. This extension follows a major amendment to the New Drug Application (NDA) submitted by Ascendis Pharma. CEO Jan Mikkelsen stated that they have responded to all FDA requests and are committed to working with the agency. Patients currently in clinical trials and the Expanded Access Program (EAP) will continue to receive their medication, and the EAP remains open for enrollment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
none
-
Rhea-AI Summary

Ascendis Pharma A/S (Nasdaq: ASND) announced significant and sustained improvements in renal function for adults with chronic hypoparathyroidism treated with TransCon PTH (palopegteriparatide) in a Phase 3 trial. The results showed a mean eGFR increase of 8.9 mL/min/1.73m2 at Week 52 and 9.0 mL/min/1.73m2 at Week 104, with well-tolerated treatment and no new safety concerns.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
-
Rhea-AI Summary

Ascendis Pharma A/S (Nasdaq: ASND) will present new TransCon PTH data at the European Congress of Endocrinology, showcasing benefits in chronic hypoparathyroidism patients. Key topics include sustained kidney function improvements and quality of life enhancements. The company's presentations highlight the positive impact of TransCon PTH treatment, emphasizing its clinical and quality-of-life benefits.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
none
Rhea-AI Summary

Ascendis Pharma reported strong financial results for the first quarter of 2024, with notable achievements including the initiation of YORVIPATH® rollout, significant revenue growth for SKYTROFA®, and key milestones for TransCon PTH and TransCon CNP.

Despite positive revenue growth and operational progress, Ascendis Pharma reported increased operating expenses, a net loss, and a decline in net finance income compared to the same period in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.76%
Tags
-
Rhea-AI Summary
Ascendis Pharma A/S (Nasdaq: ASND) will report its first quarter 2024 financial results and provide a business update on May 2, 2024. The company will host a conference call and live webcast to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences earnings
-
Rhea-AI Summary
Ascendis Pharma A/S receives MHRA approval for YORVIPATH® in Great Britain for adults with chronic hypoparathyroidism, expanding global reach and gaining orphan drug status.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
Rhea-AI Summary
Ascendis Pharma A/S executives to participate in fireside chat at Leerink Partners Global Biopharma Conference 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
conferences
-
Rhea-AI Summary
Ascendis Pharma A/S (ASND) announced the launch of TransCon™ PTH with full commercial availability in Germany and Austria, with the U.S. PDUFA date set for May 14, 2024. The company reported a total Q4 revenue of €138 million, including SKYTROFA® revenue of €64 million. It also provided a business update, highlighting the streamlined structure and processes, and the achievement of Vision 3x3. The financial results for Q4 2023 showed a significant increase in revenue and a decrease in R&D and SG&A expenses compared to the same period in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
-
Rhea-AI Summary
Ascendis Pharma A/S (ASND) executives will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The event will be held virtually, with a live webcast available on the company's website. A webcast replay will also be accessible for 30 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
conferences
Rhea-AI Summary
Ascendis Pharma A/S (ASND) will report full year 2023 financial results and provide a business update on February 7, 2024, after the close of the U.S. financial markets. A conference call and webcast will be held at 4:30 p.m. Eastern Time (ET) to discuss the results. The live webcast link will be available on the Investors & News section of the Ascendis Pharma website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9%
Tags
conferences earnings
Ascendis Pharma

Nasdaq:ASND

ASND Rankings

ASND Stock Data

9.69B
60.08M
0.78%
110.41%
6.65%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
Denmark
ABINGDON, OXFORDSHIRE